New breast cancer stem cell clues may help develop therapeutics

Researchers at Boston University School of Medicine (BUSM), under the direction of Sam Thiagalingam, PhD, have identified a new regulatory pathway that may play an important role in basal-like breast cancer (BLBC), a particularly aggressive form of breast cancer often referred to as “triple negative.” This pathway may serve as a target for the development of an effective therapeutic.  Findings appear in the journal Molecular Cancer Research.

View all posts